2013 – First POC for wound healing
UCB-MNC-derived EV are shown to accelerate wound healing in vivo, in healthy and diabetic animals
2014 – UCB-MNC-EV demonstrated to be superior to platelet-derived growth factor BB.
Possible mechanism of action uncovered.
2014 – Exogenus’ founders participate in a technology commercialization acceleration program
2015 – Provisional patent submitted to USPTO
2015 – Exogenus Therapeutics was founded by Joana Correia, Luísa Marques and Ricardo Neves, as a result of winning COHiTEC.
2015 – Newly-founded Exogenus Therapeutics secured €100K in pre-seed investment
2015 – Exclusive licensing of patent WO/2017/163132 to Exogenus Therapeutics
2015 – Exogenus Therapeutics secures €800K in seed funding.
2016 – Development of an optimized, GMP-compliant and scalable method for the production of umbilical cord-blood derived EV (Exo-101)
2016 – Exogenus Therapeutics is selected to receive support from Horizon 2020’s SME Instrument Phase 1
2017 – Joana Correia, Exogenus Therapeutic’s founder, CEO and CSO, recognized as a Young Transatlantic Innovation Leader
2017 – Exogenus Therapeutics selected as one of the most innovative Life Sciences & Medtech projects in Europe at Merck Venture Lounge
2018 – Development of a poloxamer-based hydrogel for Exo-101 delivery in wounds
2018 – Filing of international patent PCT/IB2019/058462: Compositions Comprising Small Extracellular Vesicles Derived From Umbilical Cord Blood Mononuclear Cells With Anti-Inflammatory And Immunomodulatory Properties